PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α). We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hyper...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2015/924131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545457575821312 |
|---|---|
| author | Xiaomeng Feng Xia Gao Yumei Jia Heng Zhang Qingrong Pan Zhi Yao Ning Yang Jia Liu Yuan Xu Guang Wang Xinchun Yang |
| author_facet | Xiaomeng Feng Xia Gao Yumei Jia Heng Zhang Qingrong Pan Zhi Yao Ning Yang Jia Liu Yuan Xu Guang Wang Xinchun Yang |
| author_sort | Xiaomeng Feng |
| collection | DOAJ |
| description | Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α). We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia. This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group A) and 40 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum irisin and clinical characteristics were examined. Serum irisin was significantly higher in group A compared with group B (45.15±10.48 versus 35.38±9.97 ng/ml, P<0.001) and correlated with body mass index (r=0.314, P=0.011), fasting blood glucose (r=0.399, P=0.001), total cholesterol (r=0.256, P=0.040), and high-density lipoprotein cholesterol (r=0.247, P=0.047). In multiple regression analysis after controlling for confounders, only fasting blood glucose (β=5.615, P<0.001) and high-density lipoprotein cholesterol (β=19.483, P<0.001) were independently related to serum irisin. After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline (45.15±10.48 versus 38.74±12.54 ng/ml, P=0.011). Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-α agonists may protect against metabolic disorders by improving irisin resistance. |
| format | Article |
| id | doaj-art-98be14c8fac9409ab008022340a2c35d |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-98be14c8fac9409ab008022340a2c35d2025-02-03T07:25:49ZengWileyPPAR Research1687-47571687-47652015-01-01201510.1155/2015/924131924131PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with HypertriglyceridemiaXiaomeng Feng0Xia Gao1Yumei Jia2Heng Zhang3Qingrong Pan4Zhi Yao5Ning Yang6Jia Liu7Yuan Xu8Guang Wang9Xinchun Yang10Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaIrisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α). We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia. This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group A) and 40 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum irisin and clinical characteristics were examined. Serum irisin was significantly higher in group A compared with group B (45.15±10.48 versus 35.38±9.97 ng/ml, P<0.001) and correlated with body mass index (r=0.314, P=0.011), fasting blood glucose (r=0.399, P=0.001), total cholesterol (r=0.256, P=0.040), and high-density lipoprotein cholesterol (r=0.247, P=0.047). In multiple regression analysis after controlling for confounders, only fasting blood glucose (β=5.615, P<0.001) and high-density lipoprotein cholesterol (β=19.483, P<0.001) were independently related to serum irisin. After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline (45.15±10.48 versus 38.74±12.54 ng/ml, P=0.011). Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-α agonists may protect against metabolic disorders by improving irisin resistance.http://dx.doi.org/10.1155/2015/924131 |
| spellingShingle | Xiaomeng Feng Xia Gao Yumei Jia Heng Zhang Qingrong Pan Zhi Yao Ning Yang Jia Liu Yuan Xu Guang Wang Xinchun Yang PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia PPAR Research |
| title | PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia |
| title_full | PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia |
| title_fullStr | PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia |
| title_full_unstemmed | PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia |
| title_short | PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia |
| title_sort | ppar α agonist fenofibrate decreased serum irisin levels in type 2 diabetes patients with hypertriglyceridemia |
| url | http://dx.doi.org/10.1155/2015/924131 |
| work_keys_str_mv | AT xiaomengfeng pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT xiagao pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT yumeijia pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT hengzhang pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT qingrongpan pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT zhiyao pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT ningyang pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT jialiu pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT yuanxu pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT guangwang pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia AT xinchunyang pparaagonistfenofibratedecreasedserumirisinlevelsintype2diabetespatientswithhypertriglyceridemia |